Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Shares Traded Last Trade
  36.60 2.13% 1,756.20 7,383,955 16:35:04
Bid Price Offer Price High Price Low Price Open Price
1,753.60 1,754.60 1,754.00 1,729.00 1,734.20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 34,114.00 5,442.00 87.60 20.0 89,285
Last Trade Time Trade Type Trade Size Trade Price Currency
18:45:00 O 140,000 1,749.425 GBX

Gsk (GSK) Latest News (8)

More Gsk News
Gsk Investors    Gsk Takeover Rumours
Smart Money!
GSK is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 
 JPMORGAN CLAVERHOUSE INVESTMENT TRUST PLC 4.10% 2022-05-31
 BMO UK HIGH INCOME TRUST PLC 6.62% 2022-05-31

Gsk (GSK) Discussions and Chat

Gsk Forums and Chat

Date Time Title Posts
25/6/202208:14Glaxosmithkline - The recovery29,889
24/6/202208:03GlazoSmithKline - News & Information112
29/4/202211:42GLAXOSMITHKLINE WITH CHARTS & NEWS177
29/4/202211:41GSK - just mucking around2
23/1/202114:27In Rude Health!1

Add a New Thread

Gsk (GSK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-06-24 17:45:011,749.43140,0002,449,195.00O
2022-06-24 17:22:071,698.68100,0001,698,675.00O
2022-06-24 17:22:051,703.12100,0001,703,119.00O
2022-06-24 16:51:441,751.309,610168,299.93O
2022-06-24 16:50:051,746.21116,3332,031,421.97O
View all Gsk trades in real-time

Gsk (GSK) Top Chat Posts

DateSubject
25/6/2022
09:20
Gsk Daily Update: Gsk Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,719.60p.
Gsk Plc has a 4 week average price of 1,666p and a 12 week average price of 1,646.40p.
The 1 year high share price is 1,817p while the 1 year low share price is currently 1,362.80p.
There are currently 5,083,974,547 shares in issue and the average daily traded volume is 12,957,375 shares. The market capitalisation of Gsk Plc is £89,284,760,994.41.
20/6/2022
16:32
jonjoneil: The value of GSK shares will be reduced after Haleon is taken out. I think consolidation is the process of reducing the number of GSK shares to bring the value of each new share to approximate the price immediately before the split. So you will have less GSK plus Haleon (to equal the value of your pre-split holding). So, in theory, if you sold your Haleon shares immediately after issue, and brought new GSK with the proceeds you would end up with the same number of GSK shares that you had pre-split I'm prepared to be corrected.
18/6/2022
21:47
sajad37: 13:00 What investors need to know as GSK and Pfizer spin off Haleon Some analysts see the valuation well short of the £50bn tabled by Unilever, while others reckon GSK will have divested itself of a major "headache" GSK PLC - Sensodyne is one of Haleon's big brands When Haleon PLC is spun off from GSK PLC (LSE:GSK, NYSE:GSK) next month it is expected to be the biggest stock market listing of the past decade. The indicative valuation is £42bn, which begs the question why did the UK drugs giant and its partner Pfizer turn down a £50bn offer from Unilever? This, we’ll never ascertain. The deal affects thousands of private investors, many former GSK employees. So, here’s what you need to know. Timetable July 6 – Approval for the demerger to be given by shareholders. A formality, the event is convenient for international investors as it is being staged at a hotel within the Terminal 5 complex at Heathrow. July 15 – The first part of the separation process begins. This is being done via what’s called a scrip dividend, which means each GSK investor as of the close on the 14th gets shares in the consumer business. GSK will trade on July 15 without the entitlement to shares in Haleon. Its stock is also being consolidated, which means there will be fewer shares in issue. This is to ensure the impact on the share price of the Haleon demerger is mitigated. July 18 – Haleon shares begin trading in London. July 22 – Haleon’s stock will be listed in the US. July 27 – GSK’s second quarter results. This will be the first glimpse of how the slimmed down GSK is performing. November 10 (or sometime around then) - Pfizer’s ‘lock-up’; ends. So, this is a biggie. Normally, significant shareholders such as Pfizer would be asked not to sell equity for at least six months to allow normal trading patterns to be established post-demerger. In some instances, that lock-up period has been known to extend to 18 months or two years. Pfizer, which will own 32% of Haleon, will be released of that obligation in around four months. While the American drug giant has said it will beat an orderly retreat, the market will view the Pfizer stake as a stock overhang situation. This description imagines the shares are a rock and rubble overhang on a cliff wall that has the potential to dislodge then hit and hurt the climbers below. The stock overhang can hit and hurt the share price. From November 10 on (and probably well before), Haleon stock will be under pressure anticipating Pfizer’s exit. What the brokers say Barclays Capital has trawled through 400-odd-page prospectus and distilled its findings into a far less chunky 23-page overview. Two things struck us from the note. The first, was the indicative valuation range, which, based on a price-to-earnings calculation used to assess companies in the consumer staples sector, comes up well short of the £50bn tentatively tabled by Unilever. Barclays reckons Haleon shares, once listed on July 18, could be worth anywhere from 249p to 416p, which adds up to an equity valuation of £23bn-£38bn. This is based on valuations ‘multiplesR17; ranging from 15 to 25 times earnings. The second interesting ‘takeaway̵7; from the note was the bank’s interaction with key shareholders on the issue organic sales growth – a major driver of the company’s valuation. In the note, Barclays said there was “a degree of scepticism” among investors as to whether Haleon could actually hit the 4%-7% top-line target it has set itself. Indeed, it went on to say there was “significant pushback on our 4.7% medium-term growth forecast”. Jefferies, the American bank that has a stellar reputation in the healthcare sector, has assessed the demerger from GSK’s investment perspective. It believes that by spinning out Haleon, whose stock trade is painkillers such as Advil, the UK pharma group has divested itself of a headache (its words not mine). It has based its ‘buy’ recommendation and £21 a share price target on GSK’s own medium-term growth forecasts – an average 6% increase in sales and 12%-14% compound annual growth in per share earnings. “New GSK is underappreciated, as the number-two growth profile in EU large-caps,” Jefferies said in its note. “We accept New GSK pipeline remains a work-in-progress, but catalysts are starting to emerge, and the vaccines franchise just keeps getting better.” One thing to ponder Those who hold GSK currently as income play (it yields 4.7% or thereabouts currently) will see a cut in the combined GSK/Haleon pay-out post-demerger. It is estimated that GSK will distribute around 44p a share in Haleon 11p.
17/6/2022
09:51
laurence llewelyn binliner: 18.07.2022 - 1:1 New GSK:Haleon shares issued 19.07.2022 - After the close of day 1 trading, GSK consolidates its existing shares, returning the share price to around the same as before de-merger. This will ensure comparability of the company’s earnings per share and share price with previous periods.
16/6/2022
09:34
tradermichael: Yes, "Following completion of the Demerger and listing of Haleon, GSK intends to carry out the GSK Share Consolidation. This is intended to provide consistency in the GSK share price pre- and post-separation (subject to interim market movements), in order to enable comparability between the Company’s earnings per share and share price with previous periods. "
10/6/2022
15:14
tradermichael: A brand that brings science and tech to life Today, GSK is a different company from the GlaxoSmithKline that launched in 2000, and the global context around it has shifted radically. Following the proposed demerger of its consumer healthcare business, GSK will focus purely on biopharma, with a new purpose to unite science, technology and talent to get ahead of disease together. To signal the biggest corporate change at GSK for 20 years, we helped redesign GSK’s brand, to bring to life its purpose, strategy, voice and culture. These updates reflect a GSK focused on driving innovation in the field of biopharma, with new ambitions for patients, shareholders and GSK people. A dynamic, flexible and future-ready system GSK's updated brand identity reflects its new purpose: to unite science, technology and talent to get ahead of disease together. Inspired by the striking imagery found in biosciences, the identity features numerous curved forms that evoke the highly adaptable nature of the human immune system. Housed in a redesigned shape, the ‘signal’, the dynamic new GSK logo always points the way ahead. And the identity system flexes, adapts and moves to engage audiences across the many digital, social and physical environments that brands must embrace to thrive in modern times. A brand identity to get ahead of disease together The new branding showcases the amazing diversity of GSK’s people and partners. It represents talent from across its influential worldwide network, including tens of thousands of GSK people, suppliers and innovative partners. In close collaboration with the team at GSK, we developed a branding system that would work for everyone at GSK. The new branding launched in June 2022, and is being rolled out across the business in the coming months. When a logo requires such an explanation, it does not stand alone and is not self-evident!
01/6/2022
11:12
the grumpy old men: TOP NEWS: GSK files plan for consumer arm demerger with UK regulator Wed, 1st Jun 2022 09:05 Alliance News (Alliance News) - GSK PLC on Wednesday said it has submitted to the UK Financial Conduct Authority its plan for the demerger of its consumer healthcare arm and its listing in London and New York as Haleon. The separation will take the form of a demerger of at least 80% of GSK's current 68% share of the consumer business to GSK shareholders. The remaining 32% of Consumer Healthcare currently is held by US peer Pfizer Inc. Haleon will be listed as ordinary shares in London and as American depositary shares on the New York Stock Exchange. Haleon will provide consumer healthcare products in five categories: Oral Health, Pain Relief, VMS, Respiratory Health, Digestive Health and Other. Oral Health will be its largest component, having contributed 29% of revenue in 2021. GSK will be a pure biopharmaceutical firm, focused on vaccines and specialty medicines. On Tuesday, GSK said it has agreed to pay USD2.1 billion upfront, with potentially a further USD1.2 billion coming, to acquire Boston, Massachusetts-based Affinivax. Affinivax is a clinical-stage biopharmaceutical company focused on developing a novel class of pneumococcal vaccines. GSK on Wednesday said it will carry out a share consolidation following the demerger in order to keep its share price and earnings per share comparable to earlier periods. The company called a general meeting for July 6 at the to approve the plan. The meeting will be held at the Sofitel London Heathrow, Terminal 5 hotel. "The proposed demerger is the most significant corporate change for GSK in the last 20 years, creating two new leading companies, each with clear targets for growth and the ability to positively impact the health and lives of billions of people," GSK said. GSK shares were up 0.2% at 1,736.20 pence early Wednesday in London. By Tom Waite; thomaslwaite@alliancenews.com
01/6/2022
07:26
tradermichael: Yes, https://uk.advfn.com/stock-market/london/gsk-GSK/share-news/GSK-PLC-Demerger-update-Submission-of-Documents-t/88257953 6 July General Meeting for Shareholder vote 18 July Listing of new companies on London Stock Exchange 27 July GSK Q2 Results September Haleon Interim Results
30/5/2022
11:00
tradermichael: GSK announces further appointments to Designate Haleon Board Demerger and listing of Haleon expected in July 2022 GSK plc (LSE/NYSE: GSK) has today announced the appointments of Asmita Dubey, Marie-Anne Aymerich and Bryan Supran to the Designate Haleon Board, the new independent company to be formed following the demerger of the GSK Consumer Healthcare business, expected in July 2022. These appointments follow the appointment of Sir Dave Lewis as Non-Executive Chair Designate in December 2021 and the appointment of six directors in March 2022 and complete the formation of the Designate Haleon Board. This Board will benefit from an appropriate mix of skills, experience, and diversity to support Haleon as a listed company. Sir Dave Lewis, Non-Executive Chair Designate, Haleon, said: "We are delighted to be welcoming Asmita, Marie-Anne, and Bryan as Non-Executive Directors to the future Haleon Board. Together they bring a strong understanding of the global consumer sector, as well as relevant innovation and Asia experience. These appointments now complete the Designate Board ahead of the demerger of Haleon from GSK in July 2022. I look forward to working with our new board colleagues."
26/4/2022
11:53
tradermichael: Last February, the company said sales in 2022, after the consumer unit spin-off, were expected to grow 5% to 7% and adjusted operating profit was forecast to rise 12% to 14%. Wednesday's results should give: 1. An indicator of how close to these projected (good) figures the company is performing 2. Fuller detail on the 'split'. 3. Further infromation on future dividends:GSK expects to declare a 27p per share dividend payable by the current group for the first half of 2022. This comprises 22 pence per share for new GSK and 5 pence per share representing Consumer Healthcare during the first half whilst part of the group. For the second half of 2022, new GSK continues to expect to declare a 22p per share dividend. As previously communicated, new GSK would expect to declare a dividend of 45 pence per share for 2023.
09/4/2022
18:33
zho: I've just read GSK's guidance for New GSK. They're targeting revenues of "£33 billion (CER) by 2031" with an improved "operating margin from the mid-20s% in 2021 to over 30% by 2026". If they can deliver, then a mid to high teens multiple implies CAG in the share price of 8% for the next 10 years, plus dividends. https://www.gsk.com/en-gb/media/press-releases/new-gsk-to-deliver-step-change-in-growth-and-performance-over-next-ten-years/#
Gsk share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
GSK
Gsk
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220625 08:10:11